Computational investigation of TGF-β receptor inhibitors for treatment of idiopathic pulmonary fibrosis: Field-based QSAR model and molecular dynamics simulation

[1]  Muthukumaran Sivashanmugam,et al.  Virtual screening of natural inhibitors targeting ornithine decarboxylase with pharmacophore scaffolding of DFMO and validation by molecular dynamics simulation studies , 2019, Journal of biomolecular structure & dynamics.

[2]  J. Lawson,et al.  Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors. , 2017, Bioorganic & Medicinal Chemistry Letters.

[3]  Ling Xu,et al.  Genetic polymorphism in matrix metalloproteinase‐9 and transforming growth factor‐β1 and susceptibility to combined pulmonary fibrosis and emphysema in a Chinese population , 2017, The Kaohsiung journal of medical sciences.

[4]  Yunchao Su,et al.  miR-18a-5p Inhibits Sub-pleural Pulmonary Fibrosis by Targeting TGF-β Receptor II. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  K. Youker,et al.  Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives , 2017, Canadian respiratory journal.

[6]  B. Stripp,et al.  Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis. , 2016, JCI insight.

[7]  Chiranjeevi Pasala,et al.  Inhibitor design against JNK1 through e-pharmacophore modeling docking and molecular dynamics simulations , 2016, Journal of receptor and signal transduction research.

[8]  J. Tedrow,et al.  VCAM-1 is a TGF-β1 inducible gene upregulated in idiopathic pulmonary fibrosis. , 2015, Cellular signalling.

[9]  Lirong Wang,et al.  Combined 3D-QSAR, molecular docking, and molecular dynamics study of tacrine derivatives as potential acetylcholinesterase (AChE) inhibitors of Alzheimer’s disease , 2015, Journal of Molecular Modeling.

[10]  Antti Poso,et al.  Comparative molecular field analysis and molecular dynamics studies of α/β hydrolase domain containing 6 (ABHD6) inhibitors , 2015, Journal of Molecular Modeling.

[11]  R. Chambers,et al.  The anti-fibrotic effect of inhibition of TGFβ-ALK5 signalling in experimental pulmonary fibrosis in mice is attenuated in the presence of concurrent γ-herpesvirus infection , 2015, Disease Models & Mechanisms.

[12]  Devesh Kumar,et al.  Pyrazolo[3,4-d]pyrimidines as novel inhibitors of O-acetyl-l-serine sulfhydrylase of Entamoeba histolytica: an in silico study , 2015, Journal of Molecular Modeling.

[13]  N. Chaudhuri,et al.  IPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe , 2015, Advances in Therapy.

[14]  D. Szukiewicz,et al.  Transforming Growth Factor Beta Family: Insight into the Role of Growth Factors in Regulation of Fracture Healing Biology and Potential Clinical Applications , 2015, Mediators of inflammation.

[15]  Ruidan Ma,et al.  DNA Sequence Modulates Geometrical Isomerism of the trans-8,9-Dihydro-8-(2,6-diamino-4-oxo-3,4-dihydropyrimid-5-yl-formamido)-9-hydroxy Aflatoxin B1 Adduct , 2015, Chemical research in toxicology.

[16]  Juan C Garro Martinez,et al.  QSAR and 3D-QSAR studies applied to compounds with anticonvulsant activity , 2015, Expert opinion on drug discovery.

[17]  M. Ichinose,et al.  Myriad Functions of Stanniocalcin-1 (STC1) Cover Multiple Therapeutic Targets in the Complicated Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) , 2015, Clinical medicine insights. Circulatory, respiratory and pulmonary medicine.

[18]  V. Kulkarni,et al.  Combined 2D and 3D-QSAR, molecular modelling and docking studies of pyrazolodiazepinones as novel phosphodiesterase 2 inhibitors , 2014, SAR and QSAR in environmental research.

[19]  G. Jenkins,et al.  Assessment of the effect of potential antifibrotic compounds on total and αVβ6 integrin‐mediated TGF‐β activation , 2014, Pharmacology research & perspectives.

[20]  M. Rönty,et al.  Comparative study of transforming growth factor-β signalling and regulatory molecules in human and canine idiopathic pulmonary fibrosis. , 2014, Journal of comparative pathology.

[21]  M. S. Bahia,et al.  3D-QSAR analysis of anilinoquinoline inhibitors of colony stimulating factor-1 kinase (cFMS): implementation of field-based molecular alignment , 2013, Medicinal Chemistry Research.

[22]  Amr H. Mahmoud,et al.  Applying Ligands Profiling Using Multiple Extended Electron Distribution Based Field Templates and Feature Trees Similarity Searching in the Discovery of New Generation of Urea-Based Antineoplastic Kinase Inhibitors , 2012, PloS one.

[23]  T. Maher,et al.  Current and novel drug therapies for idiopathic pulmonary fibrosis , 2012, Drug design, development and therapy.

[24]  M. Mackey,et al.  High content pharmacophores from molecular fields: a biologically relevant method for comparing and understanding ligands. , 2011, Current computer-aided drug design.

[25]  Y. Hayashizaki,et al.  Emerging new technologies in Pharmacogenomics: rapid SNP detection, molecular dynamic simulation, and QSAR analysis methods to validate clinically important genetic variants of human ABC Transporter ABCB1 (P-gp/MDR1). , 2010, Pharmacology & therapeutics.

[26]  A. Sonnenberg,et al.  Integrin–TGF‐β crosstalk in fibrosis, cancer and wound healing , 2010, EMBO reports.

[27]  L. Kavraki,et al.  Modeling protein conformational ensembles: From missing loops to equilibrium fluctuations , 2006, Proteins.

[28]  S. Kloeker,et al.  TGF-β inhibitors for the treatment of cancer , 2005 .

[29]  Andrew Leask,et al.  TGF‐β signaling and the fibrotic response , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  J. Massagué,et al.  Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus , 2003, Cell.

[31]  Allan Balmain,et al.  TGF-β signaling in tumor suppression and cancer progression , 2001, Nature Genetics.

[32]  K. Sugino,et al.  Usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment. , 2015, Respiratory investigation.